<DOC>
	<DOCNO>NCT00624468</DOCNO>
	<brief_summary>This study intend evaluate efficacy , safety tolerability atacicept compare placebo explore neuroprotective effect atacicept assess OCT subject ON CIS . The study randomize . Study medication administer via subcutaneous ( skin ) injection .</brief_summary>
	<brief_title>Atacicept Subjects With Optic Neuritis</brief_title>
	<detailed_description />
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<criteria>Diagnosis unilateral symptomatic optic neuritis first clinical manifestation within 28 day onset symptom study Day 1 Other protocol define inclusion criterion could apply Pre treatment immunosuppressant immunomodulating drug Relevant cardiac , hepatic renal disease Clinical significant abnormality blood cell count immunoglobulin level Clinical significant acute chronic infection Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>atacicept</keyword>
	<keyword>neuritis</keyword>
</DOC>